KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Operating Expenses (2016 - 2025)

TherapeuticsMD's Operating Expenses history spans 16 years, with the latest figure at $2.4 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 85.37% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $7.0 million, down 6.37%, while the annual FY2025 figure was $7.4 million, 5.86% down from the prior year.
  • Operating Expenses reached $2.4 million in Q4 2025 per TXMD's latest filing, up from $1.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $60.0 million in Q3 2021 to a low of -$77.8 million in Q4 2021.
  • Average Operating Expenses over 5 years is $8.6 million, with a median of $2.7 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: plummeted 250.77% in 2021, then soared 125.87% in 2022.
  • A 5-year view of Operating Expenses shows it stood at -$77.8 million in 2021, then skyrocketed by 125.87% to $20.1 million in 2022, then tumbled by 89.5% to $2.1 million in 2023, then crashed by 37.58% to $1.3 million in 2024, then skyrocketed by 85.37% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Operating Expenses are $2.4 million (Q4 2025), $1.6 million (Q3 2025), and $1.6 million (Q2 2025).